Biocon board approves share swap to acquire remaining BBL stake via preferential issue
Biocon · Pharmaceuticals & Biotechnology
Key highlights
- Biocon to issue up to 87,92,317 own equity shares at Rs. 376.16 (up to Rs. 330.73 Crores) to acquire up to 1,15,36,956 BBL shares; needs postal ballot approval.
- Board approved conversion of 1,125 OCDs into 4,11,11,689 BBL equity shares and 1,06,86,044 CCDs into 1,06,86,044 BBL equity shares, allotted to Biocon.
- S. R. Batliboi & Associates LLP recommended as statutory auditors for 5 years from the 48th AGM (Aug 06, 2026), replacing B S R & Co. LLP; subject to shareholder approval.
Why it's rated major development: the year-on-year change is 141% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Board Meeting Outcome for Outcome Of Board Meeting
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Biocon
- Order winNotableBiocon secures 10-year Pertuzumab supply contract in Brazil under PDP program
- Acquisition / mergerMajor developmentBiocon Limited board approves Q4 results, dividend, auditor change and BBL share swap
- Fundraise / allotmentNotableBiocon: board okays share swap for ~2% of BBL, Q4 results, Re. 0.50 dividend
- Dividend / buyback / bonusMajor development· Adverse for the businessBiocon reports Q4FY26, FY26 consolidated results; profit before exceptionals down YoY
- Acquisition / mergerNotableBiocon Limited announces acquisition of Biocon Biologics shares via preferential issue
Other dividend / buyback / bonus filings this fortnight
- Premco Global Ltd approves Q2 FY 2026-27 results, declares interim dividend, appoints auditor
- Precision Wires India board approves Sept 2026 quarter results and 35% dividend
- Dynamatic Technologies announces Q2 FY27 financial results and interim dividend
- Great Eastern Shipping approves Q2 and H1 results; declares Rs 14.40 interim dividend
- Safari Industries (India) Limited approves Q2 & H1 FY27 results, interim dividend, capex
- IRB Infrastructure Developers announces Q2 & H1 FY27 results and 2nd interim dividend
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.